DPI, BII and EBRD announce exit from KELIX bio, a leading emerging markets biopharmaceutical platform they created in 2020
The transaction is set to be one of the largest private equity exits and M&A deals in the pharmaceutical sector in Africa over the last twenty years· DPI, BII and EBRD, founding investors of KELIX bio, have entered a binding agreement to fully exit their inv...